Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Central Pharmaceuticals's interest expense for the
three
months ended in Mar. 2026 was BDT 0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was BDT-0.00 Mil.
Central Pharmaceuticals (DHA:CENTRALPHL) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Central Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as
GuruFocus does not calculate Central Pharmaceuticals's interest coverage with the available data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Central Pharmaceuticals Interest Expense Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Central Pharmaceuticals Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT-0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Expense of BDT-0.00 Mil mean?
Central Pharmaceuticals (DHA:CENTRALPHL) has a Interest Expense of BDT-0.00 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Central Pharmaceuticals and its competitors.
Is Central Pharmaceuticals' Interest Expense too high?
Central Pharmaceuticals' current Interest Expense is BDT-0.00 Mil. Overall, Central Pharmaceuticals has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Central Pharmaceuticals' Interest Expense compare to ZTS and UTHR?
Central Pharmaceuticals' Interest Expense of BDT-0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Central Pharmaceuticals and its competitors. Central Pharmaceuticals's current Interest Expense is BDT-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Central Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Central Pharmaceuticals (DHA:CENTRALPHL) is currently considered Modestly Undervalued. The stock's GF Value™ is BDT12.11, compared to a current price of BDT10.60 — trading 12.5% below its estimated fair value. The current Interest Expense is BDT-0.00 Mil. Central Pharmaceuticals' overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Central Pharmaceuticals (DHA:CENTRALPHL), the current Interest Expense is BDT-0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Central Pharmaceuticals (DHA:CENTRALPHL) Overvalued in 2026?
Based on GuruFocus' analysis, Central Pharmaceuticals stock appears to be undervalued.
The current stock price of BDT10.60 is trading 12.5% below its estimated GF Value™ of BDT12.11.
GuruFocus considers Central Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for DHA:CENTRALPHL:
Interest Expense: BDT-0.00 Mil
GF Value™: BDT12.11 vs. price of BDT10.60 (12.5% below fair value)
No single metric tells the full story. See the DHA:CENTRALPHL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Central Pharmaceuticals Ltd is engaged in the manufacturing and marketing of medicines in Bangladesh. The company manufactures finished pharmaceutical formulations, including tablets, capsules, liquids, ointments, and injectables, covering therapeutic areas such as anti-infectives, cardiovascular treatments, pain management, and gastrointestinal remedies. It conducts production and sales exclusively in the domestic market through its own facilities and distribution network. The company generates revenue from the sales of its pharmaceutical preparations.
65GF Score
Get the complete analysis for DHA:CENTRALPHL
Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:CENTRALPHL has been successfully added to your 
